AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will present a corporate update and participate in one-on-one meetings at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024.

Excerpt from:
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), effective January 1, 2024. In this role, Dr. Pitukcheewanont will provide his leadership in Lumos Pharma's efforts to hone its clinical and regulatory strategy, and he will continue to oversee medical affairs as the Company prepares to initiate its pivotal Phase 3 trial evaluating the efficacy of oral LUM-201 in treating moderate pediatric growth hormone deficiency (PGHD).

Excerpt from:
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

Investments into QDI to strengthen No. 1 industry position through profitable expansion into new geographic regions, market segments and enhanced product offerings // QDI offers best-in-class insights for research and clinical customers performing molecular testing and analysis with access to new Omics knowledge bases and improved AI capabilities // Portfolio improvements seek to alleviate informatics bottlenecks for precision medicine and precision care insights Investments into QDI to strengthen No. 1 industry position through profitable expansion into new geographic regions, market segments and enhanced product offerings // QDI offers best-in-class insights for research and clinical customers performing molecular testing and analysis with access to new Omics knowledge bases and improved AI capabilities // Portfolio improvements seek to alleviate informatics bottlenecks for precision medicine and precision care insights

See more here:
QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business

AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months

Read more:
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

Company anticipates Q4 2023 net FUROSCIX revenue to be approximately $5.9 to $6.1 million; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million

See original here:
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.

Read the original:
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Plans to advance diverse pipeline of programs in oncology and metabolic diseases

More:
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced its 2024 Platform Vision that redefines the future of CAR T by leveraging the unique attributes of allogeneic CAR T products.

Go here to see the original:
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline...

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer.

Go here to read the rest:
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics (Foresight), the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection today announced a strategic partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3, the first pivotal trial for first line (1L) consolidation treatment of large B-cell lymphoma (LBCL).

View original post here:
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal...

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Follow this link:
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Financing Led by Leading U.S. Life Sciences-focused Investors Financing Led by Leading U.S. Life Sciences-focused Investors

View post:
PolyPid Announces Private Placement for $16 Million in Gross Proceeds

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET).

Follow this link:
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated

Excerpt from:
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of American Depositary Shares (“ADSs”) representing its ordinary shares in the United States (“U.S.”) and listing on the Nasdaq Global Market (“Nasdaq”). Telix’s ordinary shares will remain listed on the Australian Securities Exchange.

Link:
Telix Announces Planned Registered Public Offering and Listing in the United States

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023, compared with $666.8 million for the year ended December 31, 2022.

See the article here:
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

DALLAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control. GRAD1405 is a single agent that has demonstrated the ability to consistently reduce three KRAS mutant proteins: KRAS G12C, G12D and G12V, which are responsible for the rapid resistance to existing therapies and a resulting loss of efficacy. This approach may eliminate the need for multiple therapeutic compounds to address the different genes. Additionally, a precursor of GRAD1405 tested in a pancreatic cancer animal model showed improved benefit, suppression of tumor growth beyond 30 days and no evidence of resistance, over existing therapies. GRAD1405 achieves the silencing of specific genes using Gradalis’ proprietary bi-shRNAi technology, which has consistently reduced targeted genes in clinical trials in multiple cancer indications.

See the rest here:
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and...

Allschwil, Switzerland, January 5, 2024

Link:
Basilea provides portfolio status update

CEO to provide update on allosteric modulator pipeline clinical and preclinical development

See the article here:
Addex to Present at Biotech Showcase™ 2024

VALNEVA

See the article here:
VALNEVA - Declaration of shares and voting rights: December 31, 2023